1. OAR@UM

Browsing by Subject Breast -- Cancer -- Treatment

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 5 to 21 of 21 < previous 
Issue DateTitleAuthor(s)
1968-03Cancer of the breast : a local studyPisani, Saviour; Sammut, Victor E.; Galea, Rose
2020Chemical composition and in vitro cytotoxic screening of sixteen commercial essential oils on five cancer cell linesNajar, Basma; Shortrende, Jorge Eduardo; Pistelli, Luisa; Buhagiar, Joseph A.
2015CIP2A expression is upregulated in triple-negative breast cancerBaldacchino, Shawn; Wastall, Laura; Saliba, Christian; Hughes, Thomas A.; Speirs, Valerie; Grech, Godfrey
2017CIP2A expression predicts recurrences of tamoxifen-treated breast cancerBaldacchino, Shawn; Wastall, Laura M.; Saliba, Christian; Hughes, Thomas A.; Scerri, Christian A.; Berwick, Angelene; Speirs, Valerie; Hanby, Andrew M; Grech, Godfrey
2014Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720Baldacchino, Shawn; Saliba, Christian; Petroni, Vanessa; Fenech, Anthony G.; Borg, Nigel; Grech, Godfrey
2015Differential expression of breast cancer signature genes following rapamycin treatmentPetroni, Vanessa; Fenech, Anthony G.; Saliba, Christian; Camilleri Podesta, Marie Therese; Baldacchino, Shawn; Grech, Godfrey
2015Differential expression of the protein phosphatase 2 (PP2A) inhibitors following PP2A activation by FTY720 in specific breast cancer cell linesBaldacchino, Shawn; Saliba, Christian; Gauci, Robert; Grixti, Maria Pia; Wastall, Laura M.; Hughes, Thomas A.; Grech, Godfrey
2008Female teenage knowledge of breast cancer and breast awarenessMuscat, Charmaine
2014FTY720 restores the activity of the phosphatase PP2A in specific breast cancer cell linesSaliba, C.; Baldacchino, S.; Borg, N.; Ellul, B.; Scerri, C.; Grech, Godfrey
2022‘In silico’ design and validation of novel cyclin dependent kinase (CDK) receptor inhibitors, using the palbociclib scaffold, a molecule for the management for breast cancer as a leadFelice, Andrew (2022)
2020A loop involving NRF2, miR‐29b‐1‐5p and AKT, regulates cell fate of MDA‐MB‐231 triple‐negative breast cancer cellsDe Blasio, Anna; Di Fiore, Riccardo; Pratelli, Giovanni; Drago‐Ferrante, Rosa; Saliba, Christian; Baldacchino, Shawn; Grech, Godfrey; Scerri, Christian A.; Vento, Renza; Tesoriere, Giovanni
2019Loss of MCL1 function sensitizes the MDA‐MB‐231 breast cancer cells to rh‐TRAIL by increasing DR4 levelsDe Blasio, Anna; Pratelli, Giovanni; Drago‐Ferrante, Rosa; Saliba, Christian; Baldacchino, Shawn; Grech, Godfrey; Tesoriere, Giovanni; Scerri, Christian A.; Vento, Renza; Di Fiore, Riccardo
2019Naphthol-derived Betti bases as potential SLC6A14 blockersPuerta, Adrián; Galán, Alexis R.; Abdilla, Roderick; Demanuele, Kaylie; Fernandes, Miguel X.; Bosica, Giovanna; Padrón, José M.
2015P010 An RNA based method to determine HER2 expression status in breast cancer patientsBaldacchino, Shawn; Sacco, Keith; Saliba, Christian; DeGaetano, James; Scerri, Christian; Grech, Godfrey
2012Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapyCampone, Mario; Bondarenko, Igor N.; Brincat, Stephen; Hotko, Y. S.; Münster, Pamela N.; Chmielowska, Ewa; Fumoleau, Pierre; Ward, Robyn L.; Bardy-Bouxin, Nathalie; Leip, Eric; Turnbull, Kathleen W.; Zacharchuk, Charles M.; Epstein, Richard John
2022Review of thermal and physiological properties of human breast tissueSaid Camilleri, Jeantide; Farrugia, Lourdes; Curto, Sergio; Rodrigues, Dario B.; Farina, Laura; Caruana Dingli, Gordon; Bonello, Julian; Farhat, Iman; Sammut, Charles V.
2015An RNA based method to determine HER2 expression status in breast cancer patientsBaldacchino, Shawn; Falzon, Sharon; Saliba, Christian; Sacco, Keith; DeGaetano, James; Scerri, Christian; Grech, Godfrey
Showing results 5 to 21 of 21 < previous